Search results for "INFECTIONS"

showing 10 items of 2671 documents

The Antiviral Properties of Cyclosporine. Focus on Coronavirus, Hepatitis C Virus, Influenza Virus, and Human Immunodeficiency Virus Infections

2020

This review updates current knowledge regarding the risk of viral infections, including COVID-19, in patients treated with cyclosporine. We also shortly refer to bacterial infections and parasitic infestations in patients treated with cyclosporin. Cyclosporine is an immunosuppressive drug, which is widely used in medicine, including in the treatment of autoimmune skin diseases in dermatology, rheumatology, ophthalmology and nephrology, and in organ transplantation. A usual concern associated with immunosuppressive treatment is the potential risk of infections. Interestingly, several data indicate a relatively low risk of infections, especially viral infections, in patients receiving cyclosp…

0301 basic medicinemedicine.medical_specialtyvirusesmedicine.medical_treatmentHepatitis C viruscoronavirusReviewBiologymedicine.disease_causeGeneral Biochemistry Genetics and Molecular BiologyVirusOrgan transplantation030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRotavirusmedicinecyclosporineinfectionstacrolimuslcsh:QH301-705.5Coronavirushuman papilloma virus infectionGeneral Immunology and MicrobiologyHepatitis Cmedicine.diseasecalcineurin inhibitorshuman herpesvirusVirologyTacrolimusAIDShepatitis flu030104 developmental biologyImmunosuppressive druglcsh:Biology (General)cyclophilinGeneral Agricultural and Biological SciencesBiology
researchProduct

The VIRSTA score, a prediction score to estimate risk of infective endocarditis and determine priority for echocardiography in patients with Staphylo…

2016

International audience; Objectives - To develop and validate a prediction score, to quantify, within 48 h of Staphylococcus aureus bacteremia (SAB) diagnosis, the risk of IE, and therefore determine priority for urgent echocardiography. Methods - Consecutive adult patients with SAB in 8 French university hospitals between 2009 and 2011 were prospectively enrolled and followed-up 3 months. A predictive model was developed and internally validated using bootstrap procedures. Results - Among the 2008 patients enrolled, 221 (11.0%) had definite IE of whom 39 (17.6%) underwent valve surgery, 25% of them within 6 days of SAB diagnosis. Ten predictors independently associated with IE were used to …

0301 basic medicinemedicine.medical_treatmentBacteremiaHospitals University0302 clinical medicine[ SDV.MP ] Life Sciences [q-bio]/Microbiology and ParasitologyInterquartile rangeVertebral osteomyelitis030212 general & internal medicineLongitudinal StudiesProspective StudiesChildbiologyEndocarditisHeartMiddle AgedStaphylococcal InfectionsImplantable cardioverter-defibrillator3. Good healthInfectious Diseases[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyEchocardiographyInfective endocarditisChild PreschoolPrognostic scoreFranceMeningitisVIRSTA scoreMicrobiology (medical)Adultmedicine.medical_specialtyStaphylococcus aureusAdolescent030106 microbiologyRisk AssessmentDecision Support Techniques03 medical and health sciencesYoung AdultInternal medicinemedicineHumans[SDV.MP] Life Sciences [q-bio]/Microbiology and ParasitologyAgedbusiness.industryC-reactive proteinmedicine.diseaseConfidence intervalSurgeryBacteremiabiology.proteinInfective endocarditisStaphylococcus aureus bacteremiabusiness
researchProduct

Interleukin-25-mediated resistance against intestinal trematodes does not depend on the generation of Th2 responses

2020

AbstractInterleukin-25 (IL-25) is recognized as the most relevant initiator of protective Th2 responses in intestinal helminth infections. It is well known that IL-25 induces resistance against several species of intestinal helminths, including the trematode Echinostoma caproni. E. caproni has been extensively used as an experimental model to study the factors determining the resistance to intestinal infections. Herein, we assessed the role of IL-25 in the generation of resistance in mice to E. caproni infections. ICR mice are permissive hosts for E. caproni in which chronic infections are developed in relation to the lack of IL-25 production in response to primary infection and the consequ…

0301 basic medicinemedicine.medical_treatmentResistanceDrug ResistanceHelminthiasisGene ExpressionEchinostoma caproniMiceTh20302 clinical medicineEchinostomaInterleukin 25Intestinal Diseases ParasiticSTAT6EchinostomiasisInterleukin-17PhenotypeIntestinesInfectious DiseasesCytokineCytokinesTrematodaSecondary infection030231 tropical medicineAntibodies HelminthTrematode InfectionsBiologyIntestinal helminthlcsh:Infectious and parasitic diseases03 medical and health sciencesTh2 CellsImmune systemMemory cellImmunitymedicineHelminthsAnimalslcsh:RC109-216RNA MessengerPermissiveResistance (ecology)ResearchImmunityDisease Models Animal030104 developmental biologyImmunoglobulin GImmunologySTAT proteinParasitologySTAT6 Transcription FactorInterleuquin-25
researchProduct

Efficient and reproducible experimental infections of rats with Blastocystis spp.

2018

Although Blastocystis spp. infect probably more than 1 billion people worldwide, their clinical significance is still controversial and their pathophysiology remains poorly understood. In this study, we describe a protocol for an efficient and reproducible model of chronic infection in rats, laying the groundwork for future work to evaluate the pathogenic potential of this parasite. In our experimental conditions, we were unable to infect rats using vacuolar forms of an axenically cultivated ST4 isolate, but we successfully established chronic infections of 4 week-old rats after oral administration of both ST3 and ST4 purified cysts isolated from human stool samples. The infection protocol …

0301 basic medicinemodèle animal[SDV]Life Sciences [q-bio]lcsh:MedicineBlastocystis Infections[SDV.BC.IC] Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]souris[SDV.IMM.II]Life Sciences [q-bio]/Immunology/Innate immunityFecesblastocyste[SDV.BC.IC]Life Sciences [q-bio]/Cellular Biology/Cell Behavior [q-bio.CB]Medicine and Health SciencesParasite hostingCystratmodèle pour les maladies humaineslcsh:Scienceblastocyst stageProtozoansGastrointestinal tractMice Inbred BALB CMice Inbred C3HMultidisciplinarybiologyaxenic cultureEukaryotaPathophysiologyanimal models3. Good health[SDV] Life Sciences [q-bio]Separation ProcessesExperimental Organism SystemsAnatomyResearch ArticlemiceColonMouse ModelsResearch and Analysis MethodsMicrobiologyculture axeniqueMicrobiology03 medical and health sciencesModel OrganismsmedicineParasitic DiseasesAnimalsHumansClinical significanceAnimal Models of Disease[SDV.IMM.II] Life Sciences [q-bio]/Immunology/Innate immunityDistillationBlastocystisHost (biology)lcsh:ROrganismsBiology and Life Sciencesbiology.organism_classificationmedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyParasitic ProtozoansRatsMice Inbred C57BLGastrointestinal TractChronic infectionDisease Models AnimalAnimal Models of Infection030104 developmental biologyBlastocystisAnimal Studieslcsh:Q[SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyParasitic Intestinal DiseasesDigestive System
researchProduct

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

2021

The approval of the first HIV-1 protease inhibitors (HIV-1 PRIs) marked a fundamental step in the control of AIDS, and this class of agents still represents the mainstay therapy for this illness. Despite the undisputed benefits, the necessary lifelong treatment led to numerous severe side-effects (metabolic syndrome, hepatotoxicity, diabetes, etc.). The HIV-1 PRIs are capable of interacting with “secondary” targets (off-targets) characterized by different biological activities from that of HIV-1 protease. In this scenario, the in-silico techniques undoubtedly contributed to the design of new small molecules with well-fitting selectivity against the main target, analyzing possible undesirabl…

0301 basic medicineon/off-targetsProtein ConformationComputer sciencemedicine.medical_treatmentHIV InfectionsLigands01 natural sciencesHIV ProteaseHIV-1 proteaseCatalytic DomainDrug DiscoveryBiology (General)DRUDITSpectroscopyMolecular StructurebiologyGeneral MedicineResearch processSmall moleculeComputer Science ApplicationsMolecular Docking SimulationChemistryligand-structure basedQH301-705.5NCI databaseComputational biologyArticleCatalysisInorganic ChemistryStructure-Activity Relationshipmolecular descriptors03 medical and health sciencesHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical ChemistryQD1-999Molecular BiologyVirtual screeningProteaseOrganic ChemistryHIV Protease Inhibitorsmolecular dockingvirtual screening0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyDrug DesignHIV-1biology.proteinInternational Journal of Molecular Sciences
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

Effects of Infant Formula With Human Milk Oligosaccharides on Growth and Morbidity: A Randomized Multicenter Trial

2017

Objectives:The aim of the study was to evaluate the effects of infant formula supplemented with 2 human milk oligosaccharides (HMOs) on infant growth, tolerance, and morbidity. Methods:Healthy infants, 0 to 14 days old, were randomized to an intact-protein, cow's milk-based infant formula (control, n=87) or the same formula with 1.0g/L 2fucosyllactose (2FL) and 0.5g/L lacto-N-neotetraose (LNnT) (test, n=88) from enrollment to 6 months; all infants received standard follow-up formula without HMOs from 6 to 12 months. Primary endpoint was weight gain through 4 months. Secondary endpoints included additional anthropometric measures, gastrointestinal tolerance, behavioral patterns, and morbidit…

0301 basic medicinesafetyMalePediatricsmedicine.medical_specialtyMEDLINEOligosaccharidesWeight Gainlaw.inventionbronchitis03 medical and health scienceschemistry.chemical_compound2'-FucosyllactoseRandomized controlled trialDouble-Blind Method2fucosyllactose; bronchitis; lacto-N-neotetraose; safety; tolerancelawMulticenter trialmedicineAnimalsHumansLacto-N-neotetraoseRespiratory Tract Infectionslacto-N-neotetraose2′fucosyllactose030109 nutrition & dieteticstoleranceMilk Humanbusiness.industryGastroenterologyOriginal Articles: NutritionInfant Newbornfood and beveragesInfantProtective Factorsmedicine.diseaseInfant Formula030104 developmental biologyMilkchemistryInfant formulaPediatrics Perinatology and Child Health2'fucosyllactose bronchitis lacto-N-neotetraose safety toleranceBronchitisFemalemedicine.symptombusinessWeight gainFollow-Up Studies
researchProduct

Subnational mapping of HIV incidence and mortality among individuals aged 15-49 years in sub-Saharan Africa, 2000-18: a modelling study

2021

Background. High-resolution estimates of HIV burden across space and time provide an important tool for tracking and monitoring the progress of prevention and control efforts and assist with improving the precision and efficiency of targeting efforts. We aimed to assess HIV incidence and HIV mortality for all second-level administrative units across sub-Saharan Africa. Methods. In this modelling study, we developed a framework that used the geographically specific HIV prevalence data collected in seroprevalence surveys and antenatal care clinics to train a model that estimates HIV incidence and mortality among individuals aged 15–49 years. We used a model-based geostatistical framework to e…

0301 basic medicinesub-Saharan AfricaMaleHIV AntibodieEpidemiologyHIV incidencesHIV Infectionsmortality rateHIV AntibodiesModelling studyHuman immunodeficiency virus prevalence0302 clinical medicineAfrica NorthernRA0421Seroepidemiologic StudiesMedicineNorthernHIV Infection030212 general & internal medicineYoung adult10. No inequalityuncertaintyMozambique11 Medical and Health SciencesHIV mortalityMortality rateIncidence (epidemiology)Incidence1. No povertyHiv incidencearticleMauritaniaHuman immunodeficiency virus infected patientArticlestrackingMiddle Agedhealth care planning3. Good healthPeer reviewLesothoAIDSInfectious DiseasesQR180A990 Medicine and Dentistry not elsewhere classifiedFemaleprenatal careanti human immunodeficiency virus agentseroepidemiologyHumanAdultAdolescentAnti-HIV AgentsImmunologyantiretroviral therapyUnit (housing)03 medical and health sciencesYoung AdultbloodHuman immunodeficiency virus infectionVirologySeroprevalenceHumanshumanDeveloping CountriesEstimationAcquired Immunodeficiency SyndromeSubnational mappingsbusiness.industrySeroepidemiologic StudieHIVAnti-HIV AgentPREVENTION030112 virologymortalitymonitoring3121 General medicine internal medicine and other clinical medicineHuman immunodeficiency virus antibodyAfricabusinessHIV incidence ; HIV mortality ; Subnational mapping ; Sub-Saharan Africa ; Local burden of disease ; Public healthDemography
researchProduct